Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Colorcon
QuintilesIMS
Fish and Richardson
Fuji
Queensland Health
Harvard Business School
Farmers Insurance
Citi
Deloitte

Generated: April 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,741,620

« Back to Dashboard

Which drugs does patent 8,741,620 protect, and when does it expire?

Patent 8,741,620 protects ELELYSO and is included in one NDA.

This patent has seventy-four patent family members in twenty-five countries.
Summary for Patent: 8,741,620
Title:Human lysosomal proteins from plant cell culture
Abstract: A device, system and method for producing glycosylated proteins in plant culture, particularly proteins having a high mannose glycosylation, while targeting such proteins with an ER signal and/or by-passing the Golgi. The invention further relates to vectors and methods for expression and production of enzymatically active high mannose lysosomal enzymes using transgenic plant root, particularly carrot cells. More particularly, the invention relates to host cells, particularly transgenic suspended carrot cells, vectors and methods for high yield expression and production of biologically active high mannose Glucocerebrosidase (GCD). The invention further provides for compositions and methods for the treatment of lysosomal storage diseases.
Inventor(s): Shaaltiel; Yoseph (Kibbutz HaSolelim, IL), Baum; Gideon (Kibbutz Ayelet HaShachar, IL), Bartfeld; Daniel (Kibbutz Moran, IL), Hashmueli; Sharon (Ramot-Naftali, IL), Lewkowicz; Ayala (Kfar-Vradim, IL)
Assignee: Protalix Ltd. (Carmiel, IL)
Application Number:13/555,243
Patent Claim Types:
see list of patent claims
Compound; Composition;

Drugs Protected by US Patent 8,741,620

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Pfizer ELELYSO taliglucerase alfa POWDER;IV (INFUSION) 022458-001 May 1, 2012 RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,741,620

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,227,230 Human lysosomal proteins from plant cell culture ➤ Sign Up
8,449,876 Human lysosomal proteins from plant cell culture ➤ Sign Up
6,391,638 Cell/tissue culturing device and method ➤ Sign Up
9,220,737 Plant cell culture expressing human lysosomal proteins and uses thereof ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Merck
Julphar
McKesson
Express Scripts
Dow
AstraZeneca
Federal Trade Commission
Baxter
Fish and Richardson

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.